ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)
Status:
Completed
Trial end date:
2019-02-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of ILT-101 (human
recombinant interleukin 2 (IL-2)) in patients with moderate to severe systemic lupus
erythematosus.